Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan-Reference-Cited by-同舟云学术

Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan

Published:2013 Issue:24 Volume:52 Page:2701-2706
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sato Akira¹,Sata Michio²,Ikeda Kenji³,Kumada Takashi⁴,Izumi Namiki⁵,Asahina Yasuhiro⁵,Osaki Yukio⁶,Chayama Kazuaki⁷,Kaneko Shuichi⁸,Sakai Akito⁸,Onji Morikazu⁹,Hiasa Yoichi⁹,Omura Takumi¹⁰,Ozeki Itaru¹⁰,Yokosuka Osamu¹¹,Shiina Shuichiro¹²,Itsubo Mariko¹³,Nishiguchi Shuhei¹⁴,Hirano Katsuharu¹⁵,Ide Tatsuya²,Sakisaka Shotaro¹⁶,Yamasaki Takahiro¹⁷,Hidaka Isao¹⁷,Tanaka Masatoshi¹⁸,Kim Soo Ryang¹⁹,Ichida Takafumi¹⁵

Affiliation:

1. Department of Gastroenterology, St. Marianna University School of Medicine, Yokohama Seibu Hospital, Japan

2. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan

3. Department of Hepatology, Toranomon Hospital, Japan

4. Department of Gastroenterology, Ogaki Municipal Hospital, Japan

5. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan

6. Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Japan

7. Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Japan

8. Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Japan

9. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Japan

10. Department of Gastroenterology, Sapporo Kosei General Hospital, Japan

11. Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Japan

12. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan

13. Department of Gastroenterology and Hepatology, Jikei University School of Medicine, Japan

14. Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Japan

15. Department of Hepatology and Gastroenterology, Juntendo Shizuoka Hospital, Japan

16. Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Japan

17. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Japan

18. Department of Gastroenterology, Kurume University Medical Center, Japan

19. Department of Gastroenterology, Kobe Asahi Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/52/24/52_52.1180/_pdf

Reference32 articles.

1. 1. World Health Organization. Global Alert and Response (GAR): Hepatitis C. 2012. Accessed 27 May 2013. http://www.who.Int/mediacentre/factsheets/fs164/en/index.html

2. 2. Center for Cancer Control and Information Services, National Cancer Center, Japan. Cancer Statistics in Japan-2011. Accessed 27 May 2013. http://ganjoho.jp/pro/statistics/en/backnumber/2012_en.html

3. 3. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37: S95-S100, 2007.

4. 4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131: 174-181, 1999.

5. 5. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28: 930-938, 1998.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents;Oncology;2024

2. The role of serum visfatin and vaspin in hepatocellular carcinoma in hepatitis C-related liver cirrhosis;Clinical and Experimental Hepatology;2023

3. Surveillance of hepatocellular carcinoma using liver stiffness in patients with hepatitis C after sustained virologic response by direct-acting antivirals;Kanzo;2022-06-01

4. Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response ( SVR ) with interferon‐based therapies and baseline characteristics;Liver Cancer International;2022-05-11

5. TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy;Journal of Gastroenterology;2018-10-31